---
document_datetime: 2025-12-29 13:42:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/thymanax.html
document_name: thymanax.html
version: success
processing_time: 0.2736853
conversion_datetime: 2025-12-31 02:00:35.732255
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Thymanax

[RSS](/en/individual-human-medicine.xml/65771)

##### Withdrawn

This medicine's authorisation has been withdrawn

agomelatine Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Thymanax](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 31 July 2022, the European Commission withdrew the marketing authorisation for Thymanax (agomelatine) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Servier (Ireland) Industries Ltd., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Thymanax was granted marketing authorisation in the EU on 19 February 2009 for treatment of major depressive disorder. The product had not been marketed in the EU since 2021.

Thymanax was a duplicate application to Valdoxan, which is marketed in several EU countries. The marketing authorisation holder will maintain the marketing authorisation for Valdoxan.

The European Public Assessment Report (EPAR) for Thymanax is updated to indicate that the marketing authorisation is no longer valid.

Thymanax : EPAR - Summary for the public

English (EN) (185.4 KB - PDF)

**First published:** 16/03/2009

**Last updated:** 08/08/2023

[View](/en/documents/overview/thymanax-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-450)

български (BG) (265.32 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/bg/documents/overview/thymanax-epar-summary-public_bg.pdf)

español (ES) (189.36 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/es/documents/overview/thymanax-epar-summary-public_es.pdf)

čeština (CS) (240.21 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/cs/documents/overview/thymanax-epar-summary-public_cs.pdf)

dansk (DA) (187.1 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/da/documents/overview/thymanax-epar-summary-public_da.pdf)

Deutsch (DE) (196.52 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/de/documents/overview/thymanax-epar-summary-public_de.pdf)

eesti keel (ET) (175.2 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/et/documents/overview/thymanax-epar-summary-public_et.pdf)

ελληνικά (EL) (282.5 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/el/documents/overview/thymanax-epar-summary-public_el.pdf)

français (FR) (193.28 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/fr/documents/overview/thymanax-epar-summary-public_fr.pdf)

hrvatski (HR) (226.52 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/hr/documents/overview/thymanax-epar-summary-public_hr.pdf)

italiano (IT) (186.03 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/it/documents/overview/thymanax-epar-summary-public_it.pdf)

latviešu valoda (LV) (234.67 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/lv/documents/overview/thymanax-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (237.82 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/lt/documents/overview/thymanax-epar-summary-public_lt.pdf)

magyar (HU) (221.45 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/hu/documents/overview/thymanax-epar-summary-public_hu.pdf)

Malti (MT) (244.64 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/mt/documents/overview/thymanax-epar-summary-public_mt.pdf)

Nederlands (NL) (191.44 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/nl/documents/overview/thymanax-epar-summary-public_nl.pdf)

polski (PL) (240.61 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/pl/documents/overview/thymanax-epar-summary-public_pl.pdf)

português (PT) (190.48 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/pt/documents/overview/thymanax-epar-summary-public_pt.pdf)

română (RO) (242.93 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/ro/documents/overview/thymanax-epar-summary-public_ro.pdf)

slovenčina (SK) (228.66 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/sk/documents/overview/thymanax-epar-summary-public_sk.pdf)

slovenščina (SL) (222.81 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/sl/documents/overview/thymanax-epar-summary-public_sl.pdf)

Suomi (FI) (178.88 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/fi/documents/overview/thymanax-epar-summary-public_fi.pdf)

svenska (SV) (185.36 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/sv/documents/overview/thymanax-epar-summary-public_sv.pdf)

Thymanax : EPAR - Risk-management-plan summary

English (EN) (301.31 KB - PDF)

**First published:** 19/02/2019

**Last updated:** 08/08/2023

[View](/en/documents/rmp-summary/thymanax-epar-risk-management-plan-summary_en.pdf)

## Product information

Thymanax : EPAR - Product Information

English (EN) (1.2 MB - PDF)

**First published:** 16/03/2009

**Last updated:** 08/08/2023

[View](/en/documents/product-information/thymanax-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-104)

български (BG) (1.67 MB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/bg/documents/product-information/thymanax-epar-product-information_bg.pdf)

español (ES) (632.66 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/es/documents/product-information/thymanax-epar-product-information_es.pdf)

čeština (CS) (1.5 MB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/cs/documents/product-information/thymanax-epar-product-information_cs.pdf)

dansk (DA) (1005.48 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/da/documents/product-information/thymanax-epar-product-information_da.pdf)

Deutsch (DE) (1.24 MB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/de/documents/product-information/thymanax-epar-product-information_de.pdf)

eesti keel (ET) (1.22 MB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/et/documents/product-information/thymanax-epar-product-information_et.pdf)

ελληνικά (EL) (1.97 MB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/el/documents/product-information/thymanax-epar-product-information_el.pdf)

français (FR) (1.31 MB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/fr/documents/product-information/thymanax-epar-product-information_fr.pdf)

hrvatski (HR) (1.48 MB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/hr/documents/product-information/thymanax-epar-product-information_hr.pdf)

íslenska (IS) (1.02 MB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/is/documents/product-information/thymanax-epar-product-information_is.pdf)

italiano (IT) (1.17 MB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/it/documents/product-information/thymanax-epar-product-information_it.pdf)

latviešu valoda (LV) (1.46 MB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/lv/documents/product-information/thymanax-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.41 MB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/lt/documents/product-information/thymanax-epar-product-information_lt.pdf)

magyar (HU) (1.36 MB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/hu/documents/product-information/thymanax-epar-product-information_hu.pdf)

Malti (MT) (1.3 MB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/mt/documents/product-information/thymanax-epar-product-information_mt.pdf)

Nederlands (NL) (1.04 MB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/nl/documents/product-information/thymanax-epar-product-information_nl.pdf)

norsk (NO) (997.47 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/no/documents/product-information/thymanax-epar-product-information_no.pdf)

polski (PL) (1.44 MB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/pl/documents/product-information/thymanax-epar-product-information_pl.pdf)

português (PT) (1.15 MB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/pt/documents/product-information/thymanax-epar-product-information_pt.pdf)

română (RO) (1.47 MB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/ro/documents/product-information/thymanax-epar-product-information_ro.pdf)

slovenčina (SK) (1.17 MB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/sk/documents/product-information/thymanax-epar-product-information_sk.pdf)

slovenščina (SL) (1.36 MB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/sl/documents/product-information/thymanax-epar-product-information_sl.pdf)

Suomi (FI) (1.06 MB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/fi/documents/product-information/thymanax-epar-product-information_fi.pdf)

svenska (SV) (1.06 MB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/sv/documents/product-information/thymanax-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0048 31/07/2022

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Thymanax : EPAR - All Authorised presentations

English (EN) (76.89 KB - PDF)

**First published:** 16/03/2009

**Last updated:** 08/08/2023

[View](/en/documents/all-authorised-presentations/thymanax-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-215)

български (BG) (95.19 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/bg/documents/all-authorised-presentations/thymanax-epar-all-authorised-presentations_bg.pdf)

español (ES) (38.56 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/es/documents/all-authorised-presentations/thymanax-epar-all-authorised-presentations_es.pdf)

čeština (CS) (83.91 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/cs/documents/all-authorised-presentations/thymanax-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (78.01 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/da/documents/all-authorised-presentations/thymanax-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (42.43 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/de/documents/all-authorised-presentations/thymanax-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (37.7 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/et/documents/all-authorised-presentations/thymanax-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (115.34 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/el/documents/all-authorised-presentations/thymanax-epar-all-authorised-presentations_el.pdf)

français (FR) (41.7 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/fr/documents/all-authorised-presentations/thymanax-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (138.35 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/hr/documents/all-authorised-presentations/thymanax-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (73.54 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/is/documents/all-authorised-presentations/thymanax-epar-all-authorised-presentations_is.pdf)

italiano (IT) (37.71 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/it/documents/all-authorised-presentations/thymanax-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (109.09 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/lv/documents/all-authorised-presentations/thymanax-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (107.35 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/lt/documents/all-authorised-presentations/thymanax-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (108.52 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/hu/documents/all-authorised-presentations/thymanax-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (102.34 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/mt/documents/all-authorised-presentations/thymanax-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (37.97 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/nl/documents/all-authorised-presentations/thymanax-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (74.61 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/no/documents/all-authorised-presentations/thymanax-epar-all-authorised-presentations_no.pdf)

polski (PL) (68.86 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/pl/documents/all-authorised-presentations/thymanax-epar-all-authorised-presentations_pl.pdf)

português (PT) (40.26 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/pt/documents/all-authorised-presentations/thymanax-epar-all-authorised-presentations_pt.pdf)

română (RO) (102.32 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/ro/documents/all-authorised-presentations/thymanax-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (72.01 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/sk/documents/all-authorised-presentations/thymanax-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (91.59 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/sl/documents/all-authorised-presentations/thymanax-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (41.43 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/fi/documents/all-authorised-presentations/thymanax-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (40.64 KB - PDF)

**First published:**

16/03/2009

**Last updated:**

08/08/2023

[View](/sv/documents/all-authorised-presentations/thymanax-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Thymanax Active substance agomelatine International non-proprietary name (INN) or common name agomelatine Therapeutic area (MeSH) Depressive Disorder, Major Anatomical therapeutic chemical (ATC) code N06AX22

### Pharmacotherapeutic group

Psychoanaleptics

### Therapeutic indication

Treatment of major depressive episodes in adults.

## Authorisation details

EMA product number EMEA/H/C/000916 Marketing authorisation holder

Servier (Ireland) Industries Ltd

Gorey Road

Opinion adopted 27/07/2006 Marketing authorisation issued 19/02/2009 Withdrawal of marketing authorisation 31/07/2022 Revision 24

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Thymanax : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (833.23 KB - PDF)

**First published:** 19/01/2010

**Last updated:** 08/08/2023

[View](/en/documents/procedural-steps-after/thymanax-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Thymanax : EPAR-H-C-000916-P46-032 - Assessment Report

Adopted

Reference Number: EMA/CHMP/613378/2022

English (EN) (1.39 MB - PDF)

**First published:** 08/08/2022

[View](/en/documents/variation-report/thymanax-epar-h-c-000916-p46-032-assessment-report_en.pdf)

Thymanax-H-C-PSUSA-00000071-201602 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

English (EN) (116.99 KB - PDF)

**First published:** 02/12/2016

**Last updated:** 08/08/2023

[View](/en/documents/scientific-conclusion/thymanax-h-c-psusa-00000071-201602-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Thymanax-PSUSA-0000071-201502 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/19569/2016

English (EN) (105.02 KB - PDF)

**First published:** 26/01/2016

**Last updated:** 08/08/2023

[View](/en/documents/scientific-conclusion/thymanax-psusa-0000071-201502-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Thymanax-H-C-916-P46-0027: EPAR - Assessment Report

Adopted

Reference Number: EMA/6251/2016

English (EN) (1.47 MB - PDF)

**First published:** 05/01/2016

**Last updated:** 08/08/2023

[View](/en/documents/variation-report/thymanax-h-c-916-p46-0027-epar-assessment-report_en.pdf)

Thymanax-H-C-916-PSUV-0021 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/717807/2014

English (EN) (124.68 KB - PDF)

**First published:** 09/12/2014

**Last updated:** 08/08/2023

[View](/en/documents/scientific-conclusion/thymanax-h-c-916-psuv-0021-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Thymanax-H-C-916-PSUV-0019 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/702809/2013

English (EN) (4.31 MB - PDF)

**First published:** 09/12/2013

**Last updated:** 08/08/2023

[View](/en/documents/variation-report/thymanax-h-c-916-psuv-0019-epar-assessment-report-variation_en.pdf)

Thymanax-H-C-916-PSUV-0017 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/740413/2013

English (EN) (84.64 KB - PDF)

**First published:** 09/12/2013

**Last updated:** 08/08/2023

[View](/en/documents/scientific-conclusion/thymanax-h-c-916-psuv-0017-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

CHMP post-authorisation summary of positive opinion for Thymanax

Adopted

Reference Number: EMA/CHMP/578213/2013

English (EN) (81.04 KB - PDF)

**First published:** 20/09/2013

**Last updated:** 08/08/2023

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-thymanax_en.pdf)

## Initial marketing authorisation documents

Thymanax : EPAR - Public assessment report

English (EN) (2.46 MB - PDF)

**First published:** 03/06/2009

**Last updated:** 08/08/2023

[View](/en/documents/assessment-report/thymanax-epar-public-assessment-report_en.pdf)

#### News on Thymanax

[EMA confirms positive benefit-risk for antidepressant Valdoxan/Thymanax (agomelatine)](/en/news/ema-confirms-positive-benefit-risk-antidepressant-valdoxan-thymanax-agomelatine) 26/09/2014

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 September 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-september-2014) 26/09/2014

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 September 2014](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-september-2014) 12/09/2014

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2013) 20/09/2013

**This page was last updated on** 08/08/2022

## Share this page

[Back to top](#main-content)